oral glp 1 brand name Ro Launches Wegovy® Pill Through Integration with Novo Nordisk and turmeric extract standardized to 95% curcuminoids GLP-Activate | Hunger & Metabolism

History of acute pancreatitis Baseline characteristics Age - 55.85 yr Female sex - 57.1% Average body weight - 210 lbs (96 kg) Average BMI - 34.65 Type 2 diabetes - 55.9% Average ALT - 67.85 U/liter Average AST - 53.0 U/liter Fibrosis stage 2 - 31.3% Fibrosis stage 3 - 68.8% Randomized treatment groups Group 1 (534 patients): Semaglutide with a target dose of 2.4 mg once weekly Group 2 (266 patients): Placebo The starting dose of semaglutide was 0.25 mg once weekly, which was increased every 4 weeks to once-weekly doses of 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg until the target dose of 2.4 mg was reached after the 16-week dose-escalation period

doi: 10.1038/nature15766 126 DawedAYMariABrownAMcDonaldTJLiLWangSet al

Williams D, Atkinson M, Evans M

Survodutide is primarily being investigated for comprehensive metabolic health, obesity, and particularly non-alcoholic fatty liver disease (NAFLD) in 2026